| dc.contributor.author |
Koech, Mathew K. |
|
| dc.contributor.author |
Ali, Shamim M. |
|
| dc.contributor.author |
Karoney, Mercy J. |
|
| dc.contributor.author |
Kigen, Gabriel |
|
| dc.date.accessioned |
2023-06-25T11:28:13Z |
|
| dc.date.available |
2023-06-25T11:28:13Z |
|
| dc.date.issued |
2022 |
|
| dc.identifier.uri |
https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-022-03647-6 |
|
| dc.identifier.uri |
http://ir.mu.ac.ke:8080/jspui/handle/123456789/7632 |
|
| dc.description.abstract |
Abacavir is a nucleoside reverse transcriptase inhibitor that is used as a component of the antiretroviral treatment regimen in the management of the human immunodeficiency virus for both adults and children. It is efficacious, but its use may be limited by a hypersensitivity reaction linked with the HLA-B*57:01 genotype. HLA-B*57:01 has been reported to be rare in African populations. Because of the nature of its presentation, abacavir hypersensitivity is prone to late diagnosis and treatment, especially in settings where HLA-B*57:01 genotyping is not routinely done. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
BMC |
en_US |
| dc.subject |
Hypersensitivity |
en_US |
| dc.subject |
HIV |
en_US |
| dc.title |
Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report |
en_US |
| dc.type |
Article |
en_US |